Patients with cancer, many who are older and on Medicare, are finding their medications are becoming unaffordable, Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation, explained at the Cost-Sharing Roundtable, co-hosted by the Patient Access Network Foundation and The American Journal of Managed Care®.
Patients with cancer, many who are older and on Medicare, are finding their medications are becoming unaffordable, Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation, explained at the Cost-Sharing Roundtable, co-hosted by the Patient Access Network Foundation and The American Journal of Managed Care® on February 23, 2018.
What are the financial hardships facing patients with cancer?
Patients with cancer, because there is a lot of innovation around cancer, and there are a lot of oral targeted treatment medications, patients’ prescription coverage tends to have tiered levels of coverage. So, most of these medications fall into the specialty tier. If they are a Medicare patient, which most patients with cancer are older at this point, they have Part D issues—Medicare Part D, which has a deductible phase, a coverage gap phase, and then the catastrophic. And even when they get into the catastrophic at 5%, these patients can’t afford their medications. It can be anywhere from $500 to over $1000 a month for their medications.
How are the financial hardships changing as cancer becomes more of a chronic condition for many patients?
Cancer is becoming more of a chronic condition. It is affecting the elderly. Elderly patients are already restricted by their incomes and their coverage. Medicare with the out-of-pocket costs for Medicare patients it’s just unaffordable. There was a statistic given earlier today [at the PAN Foundation Cost-Sharing Roundtable] that said one-third of Medicare patients spend 20% of their income on medications. It’s becoming unaffordable for Medicare patients.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More